Founded in November 2001, Jiangsu Jibeier Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) is a hi-tech enterprise specialized in drug research & development and manufacturing. With multi product series predominated by Leucogen Tablets for WBC count increasing，and Nitrendipine and Atenolol Tablets, first-in-class new drug for anti-hypertension among other hi-tech products, the Company is devoted to research & development of innovative drugs against depression, tumors, stomach illness and other diseases.
The Company has founded a professional R&D team with more than one hundred persons and a R&D tech platform based on compound preparation R&D technology, deuterated drug R&D technology, and lipidosome drug R&D technology, and a series of innovative drugs have been developed. Among them, antidepressant first-in-line new drug (JJH201501) is in Phase II clinical study, subjects have enrolled and follow-up observation is in progress; for antineoplastic new drug (JJH201601), screening of target compounds and research of preparations have been completed with substantiated significant results in pre-clinical trials. In addition, the Company plans to develop first-in-line innovative drugs, such as antacid new drug (JJH201701), new drug for treatment of cholecystitis and gall-stone (JJH201801), anti-xerophthalmia new drug Lifitegrast Derivative, weight-loss new drug Lorcaserin Hydrochloride Derivative and antidiabetic Mulberry-leaf-sourced General Flavone & Total Alkaloids Capsules. Relevant pre-clinical trials are progressing orderly in accordance with national new drug research & development requirements.
Currently 14 invention patents have been granted by China, 2 patents by the U.S., patents by Europe and 14 invention patents are pending. The Company has obtained 6 new drug certificates , 6 hi-tech products and 2 national key new products. Besides, it has been involved in drafting national drug quality standards for many products, e.g., Leucogen Tablets, Nitrendipine and Atenolol Tablets, or Aceclofenac Enteric-Coated Tablets.
| Full name | Jiangsu Jibeier Pharmaceutical Co., Ltd. |
|---|---|
| Abbreviations | Jibeier Pharmaceutical |
| Code | 688566 |
| Founded | 2001-11-13 |
| Listing | 2020-05-18 |
| Domicile | Zhenjiang City, Jiangsu Province |
| Website | www.jibeier.com.cn |
| zhaijianzhong@126.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.77 | 0.81 | 0.69 |
| R&D expenditure as a % of operating revenue | 5.93% | 5.74% | 4.04% |
| Operating Revenue | 565.97 | 542.52 | 484.96 |
| Net Income | 129.86 | 112.78 | 96.92 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 565.97 | 542.52 | 484.96 |
| Operating Costs | 62.87 | 63.89 | 64.17 |
| Operating Income | 150.56 | 130.06 | 114.22 |
| Pretax Income | 148.53 | 129.78 | 113.24 |
| Income Tax | 18.67 | 17.00 | 16.33 |
| Net Income | 129.86 | 112.78 | 96.92 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,509.89 | 365.44 | 272.89 |
| Non-current Assets-Total | 237.38 | 230.18 | 205.11 |
| Total Assets | 1,747.26 | 595.62 | 477.99 |
| Liabilities | |||
| Current Liabilities-Total | 84.01 | 65.09 | 61.26 |
| Non-current Liabilities-Total | 86.91 | 60.07 | 59.06 |
| Total Liabilities | 170.92 | 125.16 | 120.32 |
| Stockholder's Equity | |||
| Share Capital | 1,200.41 | 179.53 | 179.53 |
| Retained Profits | 369.07 | 284.22 | 171.30 |
| Minority Interests | 6.86 | 6.72 | 6.85 |
| Total Owners' Equity | 1,576.34 | 470.46 | 357.68 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 117.36 | 115.45 | 97.97 |
| Net Cash Flows-Investing | -5.80 | -29.55 | -5.29 |
| Net Cash Flows-Financing | 982.42 | -17.42 | -169.14 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 镇江中天投资咨询有限责任公司 | 54.40 | 29.10% |
| 南通汇瑞投资有限公司 | 27.20 | 14.55% |
| 耿仲毅 | 24.61 | 13.16% |
| 胡涛 | 17.68 | 9.46% |
| 南通汇祥投资咨询有限公司 | 16.32 | 8.73% |
| 国金证券－中信银行－国金证券吉贝尔高管参与科创板战略配售1号集合资产管理计划 | 4.67 | 2.50% |
| 国金创新投资有限公司 | 1.61 | 0.86% |
| 郭军 | 1.03 | 0.55% |
| 许伟 | 0.26 | 0.14% |
| 王晓晖 | 0.22 | 0.12% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.